Australia Tuberculosis Testing Market Size & Outlook, 2025-2033
Australia Tuberculosis Testing Market Insights
- As highlighted in Reed Intelligence analysis, the Australia Tuberculosis Testing Market, worth USD 25.69 Million in 2024, is forecasted to achieve USD 41.08 Million by 2033.
- The Australia market is anticipated to grow at a CAGR of 5.31% during the period 2026–2033.
- By 2024, Radiographic Test represented the largest share of the By Diagnostic Test Type market size.
- Nucleic Acid Test is expected to remain the key growth driver within By Diagnostic Test Type, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Australia accounted for 1.31% of the global Tuberculosis Testing Market size.
- By 2033, United States is expected to lead the global Tuberculosis Testing Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Tuberculosis Testing Market size by 2033.
- India is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 130.35 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 25.69 Million |
| Market Size In 2033 | USD 41.08 Million |
| Largest segment | Radiographic Test |
| Units | Revenue in USD Million |
| CAGR | 5.31% (2025-2033) |
| Segmnetation Covered | |
| By Diagnostic Test Type |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Australia Tuberculosis Testing Market By Diagnostic Test Type 2025-2033 (USD Million)
| By Diagnostic Test Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiographic Test | XX.x | XX.x | XX.x | 8.37 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Smear Microscopy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Culture-Based Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nucleic Acid Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cytokine Detection Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Drug Resistance Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Diagnostic Test Types | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia Tuberculosis Testing Market By End User 2025-2033 (USD Million)
| By End User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital/Clinic | XX.x | XX.x | XX.x | 16.69 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostics/Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
